OPRL1 antibody (AA 1-47)
Quick Overview for OPRL1 antibody (AA 1-47) (ABIN725960)
Target
See all OPRL1 AntibodiesReactivity
Host
Clonality
Conjugate
Application
-
-
Binding Specificity
- AA 1-47
-
Purpose
- Nociceptin receptor Polyclonal Antibody
-
Cross-Reactivity
- Human, Mouse, Rat
-
Predicted Reactivity
- Dog,Cow,Pig,Horse,GuineaPig
-
Purification
- Purified by Protein A.
-
Immunogen
- KLH conjugated synthetic peptide derived from mouse Nociceptin receptor
-
Isotype
- IgG
-
-
-
-
Application Notes
- WB(1:300-5000),
-
Restrictions
- For Research Use only
-
-
-
Format
- Liquid
-
Concentration
- 1 μg/μL
-
Buffer
- 0.01M TBS( pH 7.4) with 1 % BSA, 0.02 % Proclin300 and 50 % Glycerol.
-
Preservative
- ProClin
-
Precaution of Use
- This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Storage
- 4 °C,-20 °C
-
Storage Comment
- Shipped at 4C. Store at -20C for one year. Avoid repeated freeze/thaw cycles.
-
Expiry Date
- 12 months
-
-
- OPRL1 (Opiate Receptor-Like 1 (OPRL1))
-
Alternative Name
- Nociceptin receptor
-
Background
-
Synonyms: KOR3, ORGC, ORL1, Oprl, XOR1, morc, KOR-3, LC132, MOR-C, Nociceptin receptor, K3 opiate receptor, Kappa-type 3 opioid receptor, Orphanin FQ receptor, Oprl1, Oor
Background: G-protein coupled opioid receptor that functions as receptor for the endogenous neuropeptide nociceptin. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors. Signaling via G proteins mediates inhibition of adenylate cyclase activity and calcium channel activity. Arrestins modulate signaling via G proteins and mediate the activation of alternative signaling pathways that lead to the activation of MAP kinases. Plays a role in modulating nociception and the perception of pain. Plays a role in the regulation of locomotor activity by the neuropeptide nociceptin.
-
Gene ID
- 18389
-
UniProt
- P35377
Target
-